REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
This section describes the clinical use of heparin and its role in the development of heparin induced thrombocytopenia (HIT)
This section describes the clinical consequences of heparin induced thrombocytopenia (HIT)
This section lists the most frequent thromboembolic complications (TECs) that can develop in patients with heparin induced thrombocytopenia (HIT)
This section includes the severe consequences of heparin induced thrombocytopenia (HIT) and underscores the importance of prompt diagnosis and treatment of patients when HIT is suspected
This section lists the average direct medical charges associated with some of the individual thromboembolic complications (TECs) that may occur in patients with heparin induced thrombocytopenia (HIT)
This section describes the signs of heparin induced thrombocytopenia (HIT) and the timeframe in which they generally occur
This section emphasizes the need for platelet count monitoring in all patients receiving heparin to assist in the identification of patients who develop heparin induced thrombocytopenia (HIT)
This section describes the signs, symptoms, and management of heparin induced thrombocytopenia (HIT)
This section describes the laboratory tests that can be used to confirm heparin induced thrombocytopenia (HIT)
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.
H.I.T. BACK with REFLUDAN to protect life and limb
Heparin Use
Discovered in 1916, heparin has been the anticoagulant drug of choice for nearly 100 years. At this time, more than one trillion units of heparin are used annually in the United States.4 Heparin is highly effective in the prevention and treatment of numerous thromboembolic disorders, offers rapid anticoagulation, enables healthcare professionals to monitor its therapeutic activity through laboratory testing, and is relatively inexpensive.

In up to 35% of patients, however, heparin can also cause heparin-induced thrombocytopenia (HIT). (HIT type 2 will be referred to as HIT throughout this Web site.) HIT type 2, the most serious form of HIT, occurs in up to 5% of heparin patients and has potentially catastrophic sequelae.1 It is most common in patients receiving intravenous unfractionated heparin, but also occurs in patients receiving low-molecular weight heparin, heparin flushes, hemodialysis, and heparin-coated catheters.1, 2

Although the anticoagulant effects of heparin may be reversed with the use of protamine sulfate, reversal of these effects is not an effective treatment for HIT.5



Heparin-Induced Thrombocytopenia (HIT)
Heparin Use
Clinical Consequences of HIT
Thromboembolic Complications (TECs)
Iceberg Model of HIT
Economic Consequences of HIT-Associated TECs
When to Suspect HIT Type 2
Vigilant Monitoring is Critical
General Diagnosis and Treatment Algorithm for HIT
Laboratory confirmation of diagnosis

Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals